Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; magnesium stearate; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; iron oxide red; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 8000; magnesium stearate; hypromellose; colloidal anhydrous silica - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

rebel distributors corp - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 80 mg - diovan® (valsartan) is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. diovan is indicated for the treatment of heart failure (nyha class ii-iv). in a controlled clinical trial, diovan significantly reduced hospitalizations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. [ see  clinical studies (14.2)]   in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, diovan is indicated to reduce cardiovascular mortality. [ see  clinical studies (14.3 ) ] none teratogenic effects: pregnancy category d diovan, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and death when used during the second or third trimester of pregnancy. diovan can cause fetal harm when administered to a pregnant woman. if this drug is used during pregnancy, or if the p

Združene države Amerike - angleščina - NLM (National Library of Medicine)

physicians total care, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® (valsartan) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluati

Združene države Amerike - angleščina - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint nation

Združene države Amerike - angleščina - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 160 mg - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

Združene države Amerike - angleščina - NLM (National Library of Medicine)

dispensing solutions, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committe